Hepatic steatosis, GH deficiency and the effects of GH replacement: A Liverpool magnetic resonance spectroscopy study

European Journal of Endocrinology

Volumn 166, Issue 6, 2012, Pages 993-1002

  Gardner, Chris J ^a   Irwin, Andrew J ^a   Daousi, Christina ^a   McFarlane, Ian A ^a   Joseph, Franklin ^b   Bell, Jimmy D ^c   Thomas, E Louise ^c   Adams, Valerie L ^a   Kemp, Graham J ^a   Cuthbertson, Daniel J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Countess of Chester Hospital ^*  (United Kingdom)

^c MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; TRIACYLGLYCEROL;

ABDOMINAL SUBCUTANEOUS FAT; ADULT; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE TITRATION; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID STORAGE; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; BODY COMPOSITION; BODY MASS INDEX; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ENGLAND; FATTY LIVER; FEMALE; HEPATOCYTES; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INTRA-ABDOMINAL FAT; LIPID METABOLISM; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROTONS; SUBCUTANEOUS FAT; TIME FACTORS;

EID: 84862745289     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0002     Document Type: Article

References (43)

1. Adams LA, Feldstein A, Lindor KD & Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004 39 909-914. (doi:10.1002/hep.20140)
2. Ichikawa T, Hamasaki K, Ishikawa H, Ejima E, Eguchi K &Nakao K. Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency. Gut 2003 52 914. (doi:10.1136/gut.52.6.914)
3. Deepak D, Furlong NJ, Wilding JP & MacFarlane IA. Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease. Postgraduate Medical Journal 2007 83 277-280. (doi:10.1136/pgmj.2006.052241)
4. Binnerts A, Deurenberg P, Swart GR, Wilson JH & Lamberts SW. Body composition in growth hormone-deficient adults. American Journal of Clinical Nutrition 1992 55 918-923.
5. Salomon F, Cuneo RC, Hesp R & Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. New England Journal of Medicine 1989 321 1797-1803. (doi:10.1056/NEJM198912283212605)
6. Bengtsson BA, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Stahl E, Westberg B, Wilton P &Wuster C. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. Journal of Clinical Endocrinology and Metabolism 1999 84 3929-3935. (doi:10.1210/jc.84.11.3929)
7. Attanasio AF, Bates PC, Ho KK, Webb SM, Ross RJ, Strasburger CJ, Bouillon R, Crowe B, Selander K, Valle D & Lamberts SW. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status -3-year results from the HypoCCS Database. Journal of Clinical Endocrinology and Metabolism 2002 87 1600-1606. (doi:10.1210/jc.87. 4.1600)
8. Christ ER, Cummings MH & Russell-Jones DL. Dyslipidaemia in adult growth hormone (GH) deficiency and the effect of GH replacement therapy: a review. Trends in Endocrinology and Metabolism 1998 9 200-206. (doi:10.1016/S1043-2760(98)00050-2)
9. Verhelst J, Kendall-Taylor P, Erfurth EM, Price DA, Geffner M, Koltowska-Haggstrom M, Jonsson PJ, Wilton P & Abs R. Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database). Journal of Clinical Endocrinology and Metabolism 2005 90 4636-4643. (doi:10.1210/jc.2005-0185)
10. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G & Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001 50 1844-1850. (doi:10.2337/diabetes.50.8.1844)
11. van Beek AP, Wolffenbuttel BH, Runge E, Trainer PJ, Jonsson PJ &Koltowska-Haggstrom M. The pituitary gland and age-dependent regulation of body composition. Journal of Clinical Endocrinology and Metabolism 2010 95 3664-3674. (doi:10.1210/jc.2009-2506)
12. Rosen T, Eden S, Larson G, Wilhelmsen L & Bengtsson BA. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinologica 1993 129 195-200. (Pubitemid 23295679)
13. Lonardo A, Loria P, Leonardi F, Ganazzi D & Carulli N. Growth hormone plasma levels in nonalcoholic fatty liver disease. American Journal of Gastroenterology 2002 97 1071-1072.(doi:10.1111/j.1572-0241.2002.05641.x)
14. Tai TS, Lin SY & Sheu WH. Metabolic effects of growth hormone therapy in an Alstrom syndrome patient. Hormone Research 2003 60 297-301. (doi:10.1159/000074248)
15. Takano S, Kanzaki S, Sato M, Kubo T & Seino Y. Effect of growth hormone on fatty liver in panhypopituitarism. Archives of Disease in Childhood 1997 76 537-538. (doi:10.1136/adc.76.6.537)
16. Takahashi Y, Iida K, Takahashi K, Yoshioka S, Fukuoka H, Takeno R, Imanaka M, Nishizawa H, Takahashi M, Seo Y, Hayashi Y, Kondo T, Okimura Y, Kaji H, Kitazawa R, Kitazawa S & Chihara K. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology 2007 132 938-943. (doi:10.1053/j.gastro.2006.12.024)
17. Franco C, Brandberg J, Lonn L, Andersson B, Bengtsson BA &Johannsson G. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2005 90 1466-1474. (doi:10.1210/jc.2004- 1657)
18. Mekala KC & Tritos NA. Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis. Journal of Clinical Endocrinology and Metabolism 2009 94 130-137. (doi:10.1210/jc.2008-1357)
19. Pasarica M, Zachwieja JJ, Dejonge L, Redman S & Smith SR. Effect of growth hormone on body composition and visceral adiposity in middle-aged men with visceral obesity. Journal of Clinical Endocrinology and Metabolism 2007 92 4265-4270. (doi:10.1210/jc.2007-0786)
20. Anstee QM, McPherson S & Day CP. How big a problem is non-alcoholic fatty liver disease? BMJ 2011 343 d3897. (doi:10.1136/bmj.d3897)
21. Thomas EL, Hamilton G, Patel N, O'Dwyer R, Dore CJ, Goldin RD, Bell JD & Taylor-Robinson SD. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005 54 122-127. (doi:10.1136/gut.2003.036566)
22. Rico-Sanz J, Thomas EL, Jenkinson G, Mierisova S, Iles R & Bell JD. Diversity in levels of intracellular total creatine and triglycerides in human skeletal muscles observed by (1)H-MRS. Journal of Applied Physiology 1999 87 2068-2072.
23. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A & Klein S. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. PNAS 2009 106 15430-15435. (doi:10.1073/pnas.0904944106)
24. Schrauwen-Hinderling VB, Hesselink MK, Schrauwen P &Kooi ME. Intramyocellular lipid content in human skeletal muscle. Obesity 2006 14 357-367. (doi:10.1038/oby.2006.47)
25. McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L &Wiren L. The QoL-AGHDA: an instrument for the assessment of qualityof life inadultswithgrowthhormone deficiency. Quality of Life Research 1999 8 373-383. (doi:10.1023/A:1008987922774)
26. Leong KS, Walker AB, Martin I, Wile D, Wilding J & MacFarlane IA. An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease. Clinical Endocrinology 2001 54 463-468. (doi:10.1046/j.1365-2265.2001.01169.x)
27. Rico-Sanz J, Hajnal JV, Thomas EL, Mierisova S, Ala-Korpela M &Bell JD. Intracellular and extracellular skeletal muscle triglyceride metabolism during alternating intensity exercise in humans. Journal of Physiology 1998 510 (Pt 2) 615-622. (doi:10.1111/j.1469-7793.1998.615bk.x)
28. Thomas EL, Brynes AE, McCarthy J, Goldstone AP, Hajnal JV, Saeed N, Frost G & Bell JD. Preferential loss of visceral fat following aerobic exercise, measured by magnetic resonance imaging. Lipids 2000 35 769-776. (doi:10.1007/s11745-000-0584-0)
29. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH & Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. American Journal of Physiology. Endocrinology and Metabolism 2005 288 E462-E468. (doi:10.1152/ajpendo.00064.2004)
30. Vanhamme L, van den Boogaart A & Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. Journal of Magnetic Resonance 1997 129 35-43. (doi:10.1006/jmre.1997.1244)
31. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R & Graveron-Demilly D. Java-based graphical user interface for the MRUI quantitation package. Magma 2001 12 141-152. (doi:10.1007/BF02668096)
32. Savastano S, Di Somma C, Pizza G, De Rosa A, Nedi V, Rossi A, Orio F, Lombardi G, Colao A & Tarantino G. Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/ obese females. Journal of Translational Medicine 2011 9 136. (doi:10.1186/1479-5876-9-136)
33. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM & Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004 40 1387-1395. (doi:10.1002/hep.20466)
34. Egger A, Buehler T, Boesch C, Diem P, Stettler C & Christ ER. The effect of GH replacement therapy on different fat compartments: awhole-bodymagnetic resonance imaging study. European Journal of Endocrinology 2011 164 23-29. (doi:10.1530/EJE-10-0702)
35. Hazem A, Elamin MB, Bancos I, Malaga G, Prutsky G, Domecq JP, Elraiyah TA, Abu Elnour NO, Prevost Y, Almandoz JP, Zeballos-Palacios C, Velasquez ER, Erwin PJ, Natt N, Montori VM &Murad MH. Therapy in endocrine disease: body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. European Journal of Endocrinology 2012 166 13-20. (doi:10.1530/EJE-11-0558)
36. Nyenwe EA, Williamson-Baddorf S, Waters B, Wan JY&Solomon SS. Nonalcoholic fatty liver disease and metabolic syndrome in hypopituitary patients. American Journal of the Medical Sciences 2009 338 190-195. (doi:10.1097/MAJ.0b013e3181a84bde)
37. Hong JW, Kim JY, Kim YE & Lee EJ. Metabolic parameters and nonalcoholic fatty liver disease in hypopituitary men. Hormone and Metabolic Research 2011 43 48-54. (doi:10.1055/s-0030-1265217)
38. Arturi F, Succurro E, Procopio C, Pedace E, Mannino GC, Lugara M, Procopio T, Andreozzi F, Sciacqua A, Hribal ML, Perticone F & Sesti G. Nonalcoholic fatty liver disease is associated with lowcirculating levels of insulin-like growth factor-I. Journal of Clinical Endocrinology and Metabolism 2011 96 E1640-E1644. (doi:10.1210/jc.2011-1227)
39. Bredella MA, Torriani M, Thomas BJ, Ghomi RH, Brick DJ, Gerweck AV & Miller KK. Peak growth hormone-releasing hormone-arginine-stimulated growth hormone is inversely associated with intramyocellular and intrahepatic lipid content in premenopausal women with obesity. Journal of Clinical Endocrinology and Metabolism 2009 94 3995-4002. (doi:10.1210/jc.2009-0438)
40. Volzke H, Nauck M, Rettig R, Dorr M, Higham C, Brabant G &Wallaschofski H. Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. European Journal of Endocrinology 2009 161 705-713. (doi:10.1530/EJE-09-0374)
41. Ichikawa T, Nakao K, Hamasaki K, Furukawa R, Tsuruta S, Ueda Y, Taura N, Shibata H, Fujimoto M, Toriyama K & Eguchi K. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatology International 2007 1 287-294. (doi:10.1007/s12072-007-9007-4)
42. Gardner C, Richardson P, Wong C, Polavarapu N, Kemp G &Cuthbertson D. Hypothyroidism in a patient with non-alcoholic fatty liver disease. BMJ 2011 342 c7199. (doi:10.1136/bmj.c7199)
43. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ &Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology 2009 7 1104-1112. (doi:10.1016/j.cgh.2009.05.033)